Free tool
Rare disease stocks
We cover 4 companies grouped under the Rare disease theme. The median market value in the group is $11.61B. Across the group, the median move over the past trading day is +0.76%. Price change over the past year runs from −20.9% to +48.1% across the middle 80 percent of the group, with a median of +27.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| ARGX | argenx SE | $63.78B | Large cap | +50.52% | Oct 22, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $12.80B | Large cap | +13.03% | Oct 26, 2026 |
| ABVX.PA | ABIVAX Société Anonyme | $10.42B | Large cap | +42.59% | Sep 21, 2026 |
| INM | InMed Pharmaceuticals Inc. | $7.69M | Micro cap | −35.43% | Sep 23, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.